CRAWLEY, England, May 26, 2011 /PRNewswire/ — Elekta and
ScandiDos AB have entered into a non-exclusive global agreement to
distribute ScandiDos’s Delta4PT quality assurance (QA) tool.
Delta4PT can be used with Intensity Modulated Radiation Therapy
(IMRT) and Volumetric Modulated Arc Therapy (VMAT) techniques to
provide complete pre-treatment QA that ensures that the dose
prescribed in treatment plans is delivered accurately and safely to
patients.
“We’re very pleased that Elekta, a true innovator and leader in
the radiation oncology industry recognized the value of our
ScandiDos Delta4PT QA solution,” says Gorgen Nilsson, CEO at
ScandiDos. “We hope this is the beginning of an ongoing
relationship with Elekta and its customers as they strive to make
radiation therapy the safest, most effective tool in the fight
against cancer and other serious diseases.”
Delta4PT, used to verify IMRT and arc therapy delivery
techniques since 2006, enables clinicians to verify dose delivery
without compromises, in 3D; instantly analyze and approve plans;
evaluate the clinical significance of deviation; and identify the
cause of deviations. The benefits are improved efficiency by
increasing the volume of patients that can be treated as well as
enhanced verification accuracy – enabling more qualified QA
decisions to be made.
The agreement will make Delta4PT accessible to the Elekta
customer network, further complementing the Elekta QA solutions
portfolio and widening the breadth of choices for its
customers.
“As an open source, vendor neutral company, our partnership with
ScandiDos ensures that our customers can select QA solutions that
best meet their needs and clinical resources,” says Brett North,
Marketing Director, Oncology at Elekta.
About Elekta
Elekta is a human care company pioneering significant
innovations and clinical solutions for treating cancer and brain
disorders. The company deve
‘/>”/>
